BRIEF published on 12/17/2025 at 07:35, 3 months 6 days ago Sanofi publishes the document "Q4 2025 Quick Reference Guide" Financial Results Investors Sanofi Q4 2025 Modeling
BRIEF published on 12/17/2025 at 07:35, 3 months 6 days ago Sanofi Releases Q4 2025 Aide Mémoire Sanofi Financial Modeling Aide Mémoire Q4 2025 Forward-Looking
PRESS RELEASE published on 12/17/2025 at 07:30, 3 months 6 days ago Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Sanofi annonce la mise en ligne du document 'Q4 2025 Aide mémoire' pour assister la communauté financière dans la modélisation des résultats trimestriels Communication Financière Résultats Trimestriels Sanofi Document Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 3 months 6 days ago Press release: Availability of the Q4 2025 Aide memoire Sanofi announces availability of Q4 2025 Aide memoire on the company's website for financial modeling purposes. Q4 2025 results to be published on January 29, 2026 Sanofi Results Aide Mémoire Financial Modelling Q4 2025
BRIEF published on 12/15/2025 at 07:10, 3 months 8 days ago Sanofi : résultats de l'étude PERSEUS sur le tolébrutinib décevants Sclérose En Plaques Sanofi Tolebrutinib Étude PERSEUS Résultats D'étude
BRIEF published on 12/15/2025 at 07:10, 3 months 8 days ago Sanofi Halts Pursuit of Regulatory Registration for Tolebrutinib in PPMS Multiple Sclerosis Tolebrutinib PPMS Trial PERSEUS Study Sanofi R&D
BRIEF published on 12/15/2025 at 07:10, 3 months 8 days ago Sanofi renonce à l'autorisation de mise sur le marché du tolebrutinib dans le traitement de la SEP progressive primaire Sclérose En Plaques Tolebrutinib Essai PPMS Étude PERSEUS Recherche Et Développement Chez Sanofi
BRIEF published on 12/15/2025 at 07:10, 3 months 8 days ago Sanofi: PERSEUS study results on tolebrutinib disappointing Study Results Multiple Sclerosis Sanofi Tolebrutinib PERSEUS Study
BRIEF published on 12/15/2025 at 07:05, 3 months 8 days ago Le dépôt de la demande d'autorisation de mise sur le marché du tolebrutinib de Sanofi est retardé. FDA Sclérose En Plaques Sanofi Tolebrutinib Retard Réglementaire
PRESS RELEASE published on 12/15/2025 at 07:05, 3 months 8 days ago Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis Sanofi updates on tolebrutinib in primary progressive multiple sclerosis, PERSEUS phase 3 study did not meet primary endpoint. Safety profile consistent. Financial impacts discussed Sanofi Tolebrutinib Primary Progressive Multiple Sclerosis PERSEUS Phase 3 Study Financial Considerations
Published on 03/23/2026 at 08:00, 2 hours 28 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 8 hours 28 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 09:19, 1 hour 9 minutes ago Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 1 hour 28 minutes ago EQS Group launches Risk Management module to support continuous data and AI risk oversight
Published on 03/23/2026 at 08:10, 2 hours 18 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
